# EDGAR Filing Document

**Accession Number:** 0001900304
**File Stem:** 0001654954-25-007805
**Filing Date:** 2025-7
**Character Count:** 10310
**Document Hash:** e129200f5c1e2b72c8745c9c000ca8bb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-25-007805.hdr.sgml**: 20250707

**ACCESSION NUMBER**: 0001654954-25-007805

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250707

**FILED AS OF DATE**: 20250707

**DATE AS OF CHANGE**: 20250707

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Haleon plc
- **CENTRAL INDEX KEY:** 0001900304
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41411
- **FILM NUMBER:** 251107032

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING 5, FIRST FLOOR
- **STREET 2:** THE HEIGHTS
- **CITY:** WEYBRIDGE
- **STATE:** X0
- **ZIP:** KT13 0NY
- **BUSINESS PHONE:** 44 1932 822000

**MAIL ADDRESS:**
- **STREET 1:** BUILDING 5, FIRST FLOOR
- **STREET 2:** THE HEIGHTS
- **CITY:** WEYBRIDGE
- **STATE:** X0
- **ZIP:** KT13 0NY

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DRVW 2022 Ltd
- **DATE OF NAME CHANGE:** 20211217

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **FORM 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

 **For the month of July 2025**

 **Commission File Number: 001-41411**

 **Haleon plc**

(Translation of registrant's name into English)

 **Building 5, First Floor, The Heights,**

 **Weybridge, Surrey, KT13 0NY**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

 **EXHIBIT INDEX**

<u>Exhibit Number</u> <u>Description</u> <br> <u> 99.1 </u> 07 July 2025 - "Historic Proforma Category Financial Performance"

99.1 ![](a9604p000.jpg)

 **Haleon plc: Historic Proforma Category Financial Performance**

**7 July 2025:** Haleon plc (the "Company" or "Haleon") today releases the historical proforma category financial information, aligned with the announcement at the Capital Markets Day on 1 May 2025. Haleon will now be reporting six categories: Oral Health; Vitamins, Minerals, and Supplements (VMS); Pain Relief; Respiratory Health; Digestive Health; and Therapeutic Skin Health and Other.

Compared to previous reporting, the new structure:

● Splits out Digestive Health & Other into Digestive Health, and
Therapeutic Skin Health and Other

● Smokers Health which had previously been reported as part of
Digestive Health and Other will now be included in Respiratory
Health

● There are no changes to other categories not outlined
above

We will begin reporting in this new category structure at our 2025 Half Year Results on 31 July 2025. The purpose of this change is to better align Haleon's reporting with the strategic opportunities ahead as well as improve visibility of Haleon's financial performance. Haleon's geographical split remains unchanged.

Detailed below is the quarterly pro-forma actual and comparative financial information on this basis. Definitions for non-IFRS measures can be found on pages 19-27 in Haleon's 2024 Full Year Results, and pages 43-50 in Haleon's Annual Report and Form 20-F 2024.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  **Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)** | **Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)** | **Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)** | **Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)** | **Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)** | **Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)** | **Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)** |
|  | **2023** | **2023** | **2023** | **2024** | **2024** | **2024** |
|  | **£m revenue** | **Organic Revenue Growth** | **Reported Revenue Growth** | **£m revenue** | **Organic Revenue Growth** | **Reported Revenue Growth** |
| Oral Health | 3136 | 10.6% | 6.1% | 3312 | 9.6% | 5.6% |
| VMS | 1640 | 0.9% | -2.1% | 1696 | 7.6% | 3.4% |
| Pain Relief | 2652 | 7.4% | 4.0% | 2564 | 0.1% | -3.3% |
| Respiratory Health | 2244 | 11.7% | 8.2% | 2122 | 1.0% | -5.4% |
| Digestive Health | 1012 | 5.8% | 1.9% | 1029 | 5.5% | 1.7% |
| Therapeutic Skin Health and Other | 618 | 8.8% | 1.5% | 510 | 9.8% | -17.5% |
| **TOTAL** | **11302** | **8.0%** | **4.1%** | **11233** | **5.0%** | **-0.6%** |

---

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Restated quarterly reported revenue by category (unaudited)** | **Restated quarterly reported revenue by category (unaudited)** | **Restated quarterly reported revenue by category (unaudited)** | **Restated quarterly reported revenue by category (unaudited)** | **Restated quarterly reported revenue by category (unaudited)** | **Restated quarterly reported revenue by category (unaudited)** |  |  |  |  |  |  |
|  | **2023** | **2023** | **2023** | **2023** | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** |
| **£m** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** |
| Oral Health | 811 | 778 | 790 | 757 | 3136 | 854 | 829 | 810 | 819 | 3312 | 880 |
| VMS | 405 | 411 | 410 | 414 | 1640 | 422 | 435 | 407 | 432 | 1696 | 416 |
| Pain Relief | 724 | 681 | 636 | 611 | 2652 | 662 | 641 | 628 | 633 | 2564 | 661 |
| Respiratory Health | 638 | 455 | 563 | 588 | 2244 | 590 | 454 | 581 | 497 | 2122 | 525 |
| Digestive Health | 259 | 256 | 234 | 263 | 1012 | 256 | 264 | 239 | 270 | 1029 | 254 |
| Therapeutic Skin Health and Other | 149 | 171 | 165 | 133 | 618 | 135 | 152 | 115 | 108 | 510 | 117 |
| **TOTAL** | **2986** | **2752** | **2798** | **2766** | **11302** | **2919** | **2775** | **2780** | **2759** | **11233** | **2853** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Restated quarterly organic revenue growth by category (unaudited)** | **Restated quarterly organic revenue growth by category (unaudited)** | **Restated quarterly organic revenue growth by category (unaudited)** | **Restated quarterly organic revenue growth by category (unaudited)** | **Restated quarterly organic revenue growth by category (unaudited)** | **Restated quarterly organic revenue growth by category (unaudited)** |  |  |
|  | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** |
| **%** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** |
| Oral Health | 10.6% | 10.6% | 9.1% | 8.2% | 10.6% | 9.6% | 6.6% |
| VMS | 0.9% | 9.9% | 8.5% | 3.7% | 8.2% | 7.6% | 0.9% |
| Pain Relief | 7.4% | -4.8% | -4.0% | 3.1% | 7.4% | 0.1% | 2.6% |
| Respiratory Health | 11.7% | -2.7% | 1.3% | 8.2% | -2.6% | 1.0% | 0.7% |
| Digestive Health | 5.8% | 2.2% | 5.2% | 9.0% | 5.8% | 5.5% | 2.3% |
| Therapeutic Skin Health and Other | 8.8% | 7.4% | 10.7% | 0.7% | 24.2% | 9.8% | 10.4% |
| **TOTAL** | **8.0%** | **3.0%** | **4.1%** | **6.1%** | **6.8%** | **5.0%** | **3.5%** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Restated quarterly reported revenue growth by category (unaudited)** | **Restated quarterly reported revenue growth by category (unaudited)** | **Restated quarterly reported revenue growth by category (unaudited)** | **Restated quarterly reported revenue growth by category (unaudited)** | **Restated quarterly reported revenue growth by category (unaudited)** |  |  |  |
|  | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** |
| **%** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** |
| Oral Health | 6.1% | 5.3% | 6.6% | 2.5% | 8.2% | 5.6% | 3.0% |
| VMS | -2.1%  | 4.2% | 5.8% | -0.7% | 4.3% | 3.4% | -1.4% |
| Pain Relief | 4.0%  | -8.6% | -5.9% | -1.3% | 3.6% | -3.3% | -0.2% |
| Respiratory Health | 8.2%  | -7.5% | -0.2% | 3.2% | -15.5% | -5.4% | -11.0% |
| Digestive Health | 1.9%  | -1.2% | 3.1% | 2.1% | 2.7% | 1.7% | -0.8% |
| Therapeutic Skin Health and Other | 1.5%  | -9.4% | -11.1% | -30.3% | -18.8% | -17.5% | -13.3% |
| **TOTAL** | **4.1%**  | **-2.2%** | **0.8%** | **-0.6%** | **-0.3%** | **-0.6%** | **-2.3%** |

---

 **Enquiries**

---

| | | | |
|:---|:---|:---|:---|
| **Investors** | **Investors** | **Media** | **Media** |
| Jo Russell | +44 7787 392441 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel  | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
| Emma White | +44 7823 523562 |  |  |
| Email: investor-relations@haleon.com | Email: investor-relations@haleon.com | Email: corporate.media@haleon.com | Email: corporate.media@haleon.com |

---

 **About Haleon**

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as *Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu* and *Voltaren* - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

 **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **HALEON PLC**<br> *(Registrant)* | **HALEON PLC**<br> *(Registrant)* |
| Date: July 07, 2025 | By: | /s/ Amanda Mellor | /s/ Amanda Mellor |
|  |  | Name: | Amanda Mellor |
|  |  | Title: | Company Secretary |

---